[EN] FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY [FR] DÉRIVÉS BENZIMIDAZOLES TRICYCLIQUES CONDENSÉS COMME MODULATEURS DE L'ACTIVITÉ DU TNF
[EN] FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY [FR] DÉRIVÉS BENZIMIDAZOLES TRICYCLIQUES CONDENSÉS COMME MODULATEURS DE L'ACTIVITÉ DU TNF
FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY
申请人:UCB Biopharma SPRL
公开号:EP3080121B1
公开(公告)日:2019-09-04
Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity
申请人:UCB BIOPHARMA SPRL
公开号:US20160304523A1
公开(公告)日:2016-10-20
A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.